Asian Journal of Pharmaceutical Research

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Review on Dipeptidyl Peptidase IV Inhibitors as a Newer Target for Diabetes Mellitus Treatment


Affiliations
1 Institute of Chemical Technology, Mumbai, India
     

   Subscribe/Renew Journal


Diabetes Mellitus (Type 2) is a major health issue all over the world. It is rapidly growing metabolic disorder characterized by hyperglycaemia with disturbances in carbohydrate, fat and protein metabolism. According to the International Diabetes Federation, more than 380 million people in the world suffer from Diabetes and this number will rise beyond 592 million in less than 25 years. The main classes of anti-diabetic drugs (biguanides, sulphonylureas, α-glucosidase inhibitors, thiazolidinediones, meglitinides) have side effects like weight gain and hypoglycaemia which makes them unsuitable for long term use. Thus newer anti-diabetic agents are still in need. Dipeptidyl Peptidase IV inhibitors have been found to be effective in the treatment of Type 2 Diabetes. DPP IV plays a major role in glucose metabolism. It is responsible for inactivation of incretins like GLP-1. Dipeptidyl Peptidase IV inhibitors increase insulin secretion by enhancing the level of incretin hormones. These incretin hormones are responsible for maintaining postprandial blood glucose levels by stimulating insulin secretion.

Keywords

Diabetes Mellitus, Anti-Diabetic, DPP IV, Incretinharmone.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Alberti KG and Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine : A Journal of the British Diabetic Association. 1998;15(7):539–53.

  • Shetty, P. (2012). India ’ s diabetes time bomb. Nature, 485(7398), S14–S16.

  • Bruton, L.; Parker, K.; Blementhal, D.; Buxton, I. (2008). Goodman and Gilman’s Manual of Pharmacology and Therapeutics.

  • Tiwari N et al. Clinical Pharmacology Therapeutic Targets for Diabetes Mellitus: An Update. Clinical Pharmacology and Biopharmaceutics,. 2014; 3(1): 1–10.

  • Theodorakis MJ et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. American Journal of Physiology. Endocrinology and Metabolism. 2006;290(3): E550–E559.

  • Verspohl EJ . Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacology and Therapeutics. 2009; 124(1): 113–38.

  • Weber AE. Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes. Journal of Medicinal Chemistry. 2004; 47: 4135–4141.

  • Rasmussen HB et al. Crystal structure of human dipeptidyl peptidase IV / CD26 in complex with a substrate analog. Nature Structural Biology. 2004;10(1); 19–25.

  • Patel BD and Ghate MD. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 ( DPP-4 ) inhibitors. European Journal of Medicinal Chemistry. 2014;74: 574–605.

  • Feng J et al. Discovery of Alogliptin : A Potent, Selective , Bioavailable , and Efficacious Inhibitor of Dipeptidyl Peptidase IV. Journal of medicinal chemistry. 2007;50: 2297–2300.

  • Magnin DR et al. Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability : Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of r -Aminoacyl- L - cis -4 , 5-methanoprolinenitrile-Based Inhibitors. Journal of Medicinal Chemistry. 2004; 47: 2587–2598.

  • Wang L et al . Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors. European Journal of Medicinal Chemistry. 2009;44(8); 3318–22.

  • Tang PC et al. Design and synthesis of DPP-4 inhibitor for the treatment of type 2 diabetes. Chinese Chemical Letters. 2010; 21(3): 253–256.

  • KatoN et al. Synthesis and pharmacological characterization of potent, selective, and orally bioavailable isoindoline class dipeptidyl peptidase IV inhibitors. Organic and Medicinal Chemistry Letters. 2011;1(1): 7.

  • Van der Veken P et al. Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases. Journal of Medicinal Chemistry. 2005; 48(6): 1768–80.

  • Belyaev A et al. Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors. Journal of Medicinal Chemistry. 1999;42(6): 1041–52.

  • Yoshida T et al. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for t. Bioorganic and Medicinal Chemistry. 2012; 20(19): 5705–19.

  • Yoshida T et al Fused bicyclic heteroarylpiperazine-substituted L-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group. Bioorganic and Medicinal Chemistry. 2012; 20(16); 5033–41.

  • Brockunier LL et al. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. Bioorganic and Medicinal Chemistry Letters. 2004;14(18); 4763–6.

  • Kim HJet al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorganic and Medicinal Chemistry Letters. 2011;21(12): 3809–12.

  • Biftu T.(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorganic and Medicinal Chemistry Letters. 2007;17(1): 49–52.

  • Kim et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorganic and Medicinal Chemistry Letters. 2011;21(12): 3809– 12.

  • Eckhardt M et al. 8- ( 3- ( R ) -Aminopiperidin-1-yl ) -7-but-2-ynyl-3- Highly Potent , Selective , Long-Acting , and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes . Journal of Medicinal Chemistry. 2008; 50: 6450–6453.

  • Wallace MB. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorganic and Medicinal Chemistry Letters. 2008; 18(7): 2362– 7.

  • Kaczanowska K et al. Design, Synthesis, and in Vitro Evaluation of Novel Aminomethyl-pyridines as DPP-4 Inhibitors. ACS Medicinal Chemistry Letters. 2010;1(9):530–535.

  • Mattei P et al. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorganic and Medicinal Chemistry Letters. 2010; 20(3): 1109–13.

  • Banno Yet al. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554. Bioorganic and Medicinal Chemistry. 2011;19(16): 4953–70

  • Maezaki H et al. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554. Bioorganic and Medicinal Chemistry. 2011;19(15): 4482–98.

  • Xiao P et al. Discovery of dipeptidyl peptidase IV ( DPP4 ) inhibitors based on a novel indole scaffold. Chinese. 2014; 25: 673–676.


Abstract Views: 594

PDF Views: 0




  • Review on Dipeptidyl Peptidase IV Inhibitors as a Newer Target for Diabetes Mellitus Treatment

Abstract Views: 594  |  PDF Views: 0

Authors

Kavita Chandramore
Institute of Chemical Technology, Mumbai, India

Abstract


Diabetes Mellitus (Type 2) is a major health issue all over the world. It is rapidly growing metabolic disorder characterized by hyperglycaemia with disturbances in carbohydrate, fat and protein metabolism. According to the International Diabetes Federation, more than 380 million people in the world suffer from Diabetes and this number will rise beyond 592 million in less than 25 years. The main classes of anti-diabetic drugs (biguanides, sulphonylureas, α-glucosidase inhibitors, thiazolidinediones, meglitinides) have side effects like weight gain and hypoglycaemia which makes them unsuitable for long term use. Thus newer anti-diabetic agents are still in need. Dipeptidyl Peptidase IV inhibitors have been found to be effective in the treatment of Type 2 Diabetes. DPP IV plays a major role in glucose metabolism. It is responsible for inactivation of incretins like GLP-1. Dipeptidyl Peptidase IV inhibitors increase insulin secretion by enhancing the level of incretin hormones. These incretin hormones are responsible for maintaining postprandial blood glucose levels by stimulating insulin secretion.

Keywords


Diabetes Mellitus, Anti-Diabetic, DPP IV, Incretinharmone.

References